First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison

References

• Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159(1):335–349.e15. PMID: 32247694; PMCID: PMC8630546. doi:10.1053/j.gastro.2020.02.068
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. New Engl J Med. 2008;359(4):378–390.
   PubMed Web of Science ®Google Scholar
• Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first- line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Chan SL, Kudo M, et al. Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA. J Clin Oncol. 2022;40(4_suppl):379.
   Web of Science ®Google Scholar
• Journal Onkologie. Available from: https://www.journalonko.de/news/lesen/hcc-nsclc-zulassung-durvalumab-tremelimumab. Accessed May 9, 2023.
   Google Scholar
• Niizeki T, Tokunaga T, Takami Y, et al. Comparison of efficacy and safety of atezolizumab plus bevacizumab and lenvatinib as first-line therapy for unresectable hepatocellular carcinoma: a propensity score matching analysis. Target Oncol. 2022;17(6):643–653. PMID: 36272060; PMCID: PMC9684293. doi:10.1007/s11523-022-00921-x
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Brandi G. Systemic adjuvant treatment in hepatocellular carcinoma: tempted to do something rather than nothing. Future Oncol. 2020;16(32):2587–2589. PMID: 32772560. doi:10.2217/fon-2020-0669
   PubMed Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361–369. PMID: 34798793. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Kucharz J, et al. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis. Cancer Immunol Immunother. 2023;72(6):1365–1379. PMID: 36633661. doi:10.1007/s00262-022-03349-4
   PubMed Web of Science ®Google Scholar
• Santoni M, Rizzo A, Mollica V, et al. The impact of gender on The efficacy of immune checkpoint inhibitors in cancer patients: the MOUSEION-01 study. Crit Rev Oncol Hematol. 2022;170:103596. PMID: 35031442. doi:10.1016/j.critrevonc.2022.103596
   PubMed Web of Science ®Google Scholar
• Vogel A, Cervantes A, Chau I, et al.; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv238–iv255. PMID: 30285213. doi:10.1093/annonc/mdy308
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address: [email protected]; European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. PMID: 29628281. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Rothman KJ. Epidemiology: An Introduction – Rothman. Oxford university press; 2012:226.
   Google Scholar
• Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23(1):77–90.
   PubMed Web of Science ®Google Scholar
• Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. PMID: 34902530. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Fulgenzi CAM, Scheiner B, Korolewicz J, et al. Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials. JHEP Rep. 2023;5(5):100702. PMID: 37025943; PMCID: PMC10070142. doi:10.1016/j.jhepr.2023.100702
   PubMedGoogle Scholar
• Finn RS, Kudo M, Merle P, et al. Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC) [Abstract LBA34]. Ann Oncol. 2022;33(Suppl. 7):S808–S869.
   Web of Science ®Google Scholar
• Du S, Cao K, Wang Z, Lin D. Clinical efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib in the treatment of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Medicine. 2023;102(23):e33852. PMID: 37335628; PMCID: PMC10256357. doi:10.1097/MD.0000000000033852
   PubMed Web of Science ®Google Scholar
• Jost-Brinkmann F, Demir M, Wree A, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: results from a German real-world cohort. Aliment Pharmacol Ther. 2023;57(11):1313–1325. PMID: 36883351. doi:10.1111/apt.17441
   PubMed Web of Science ®Google Scholar
• McNamara MG, Slagter AE, Nuttall C, et al. Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis. Eur J Cancer. 2018;105:1–9.
   PubMed Web of Science ®Google Scholar
• Marrero JA, Kudo M, Venook AP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65(6):1140–1147. PMID: 27469901. doi:10.1016/j.jhep.2016.07.020
   PubMed Web of Science ®Google Scholar
• Espinoza M, Muquith M, Lim M, et al. Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: post-hoc analysis of imbrave150. Gastroenterology. 2023;165(1):286–288.e4. PMID: 36894034. doi:10.1053/j.gastro.2023.02.042
   PubMed Web of Science ®Google Scholar
• Pfister D, Núñez NG, Pinyol R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;592:450–456.
   PubMed Web of Science ®Google Scholar
• Haber PK, Puigvehí M, Castet F, et al. Evidence-based management of hepatocellular carcinoma: systematic review and meta-analysis of randomized controlled trials (2002–2020). Gastroenterology. 2021;161(3):879–898.
   PubMed Web of Science ®Google Scholar
• Inada Y, Mizukoshi E, Seike T, et al. Characteristics of immune response to tumor-associated antigens and immune cell pro- file in patients with hepatocellular carcinoma. Hepatology. 2019;69(2):653–665.
   PubMed Web of Science ®Google Scholar
• Chew V, Lee YH, Pan L, et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. Gut. 2019;68(2):335–346. PMID: 29440463; PMCID: PMC6352403. doi:10.1136/gutjnl-2017-315485
   PubMed Web of Science ®Google Scholar
• de la Torre-Aláez M, Matilla A, Varela M, et al. Nivolumab after selective internal radiation therapy for the treatment of hepatocellular carcinoma: a Phase 2, single-arm study. J Immunother Cancer. 2022;10(11):e005457. PMID: 36450386; PMCID: PMC9716796. doi: 10.1136/jitc-2022-005457
   PubMed Web of Science ®Google Scholar
• Number P.IMMUTACE: a phase 2 single-arm, open-label study of transarterial chemoembolization in combination with nivolumab performed for intermediate-stage hepatocellular carcinoma. Gastroenterol Hepatol. 2021;17(11 Suppl 6):16–17. PMID: 35611263; PMCID: PMC9122047.
   Google Scholar
• Scheiner B, Pomej K, Kirstein MM, et al. Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. J Hepatol. 2022;76(2):353–363. PMID: 34648895. doi:10.1016/j.jhep.2021.09.035
   PubMed Web of Science ®Google Scholar
• Edeline J, Meyer T, Blanc JF, Raoul JL. New challenges facing systemic therapies of advanced HCC in the Era of different first-line immunotherapy-based combinations. Cancers. 2022;14(23):5868. PMID: 36497349; PMCID: PMC9739025. doi:10.3390/cancers14235868
   PubMed Web of Science ®Google Scholar